Reference Pricing of Pharmaceuticals for Medicare: Evidence From Germany, the Netherlands, and New Zealand

Loading...
Thumbnail Image
Penn collection
Health Care Management Papers
Degree type
Discipline
Subject
Insurance
Medical Education
Other Business
Pharmacoeconomics and Pharmaceutical Economics
Pharmacy Administration, Policy and Regulation
Funder
Grant number
License
Copyright date
Distributor
Related resources
Author
Danzon, Patricia. M
Ketcham, Jonathan. D
Contributor
Abstract

This paper describes three prototypical systems of therapeutic reference pricing (RP) for pharmaceuticals—Germany, the Netherlands, and New Zealand—and examines their effects on the availability of new drugs, reimbursement levels, manufacturer prices, and out-of-pocket sur-charges to patients. RP for pharmaceuticals is not simply analogous to a defined contribution approach to subsidizing insurance coverage. Although a major purpose of RPis to stimulate competition, theory suggests that the achievement of this goal is unlikely, and this is confirmed by the empirical evidence. Other effects of RPdiffer across countries in predictable ways, reflecting each country’s system design and other cost-control policies. New Zealand’s RPsystem has reduced reimbursement and limited the availability of new drugs, particularly more expensive drugs. Compared to these three countries, if RP were applied in the United States, it would likely have a more negative effect on prices of on-patent products because of the more competitive U.S. generic market, and on research and development (R&D) and the future supply of new drugs, because of the much larger U.S. share of global pharmaceutical sales.

Advisor
Date Range for Data Collection (Start Date)
Date Range for Data Collection (End Date)
Digital Object Identifier
Series name and number
Publication date
2004-01-01
Journal title
Forum for Health Economics & Policy
Volume number
Issue number
Publisher
Publisher DOI
Journal Issue
Comments
Recommended citation
Collection